Jim Wilson, a seminal figure in the field of gene therapy, is departing the University of Pennsylvania (UPenn) after an illustrious career spanning decades. His decision to step down marks a significant juncture for both the institution and the broader gene therapy landscape. Over the years, Wilson
Pulmonary arterial hypertension (PAH) is a debilitating and life-threatening condition characterized by the blockage and narrowing of pulmonary arterioles. Current treatment options primarily focus on symptomatic relief, especially through the use of vasodilators. These medications help widen blood
The FDA's recent approval of a new treatment for severe alopecia areata marks a significant advance in addressing this challenging condition. Deuruxolitinib, branded as Leqselvi and developed by Sun Pharmaceutical Industries, will now compete with existing treatments from Eli Lilly and Pfizer,
The field of autoimmune disease treatment is witnessing groundbreaking innovations, with Cartesian Therapeutics making headlines for its latest Phase 2 clinical trial results of Descartes-08. This experimental cell therapy aims to bring hope to patients suffering from myasthenia gravis, a rare and
Artiva Biotherapeutics has made headlines with its successful initial public offering (IPO), raising an impressive $167 million. This significant milestone not only highlights Artiva's strategic pivot toward autoimmune disease treatments using donor-derived cell therapies but also marks a
The recent $571.5 million licensing agreement between SK Biopharmaceuticals Co., Ltd., and Full-Life Technologies Limited marks a significant milestone in the biotech industry. This exclusive deal grants SK Biopharmaceuticals the rights to develop, manufacture, and commercialize FL-091, an